Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025

Your email address will not be published. Required fields are marked *

Name *

Email *

Website

Comment *

Save my name, email, and website in this browser for the next time I comment.